Viventia Bio

General Information

We are a biologics oncology company focused on designing, engineering and developing targeted protein therapeutics, or TPTs. Our most advanced product candidates, Vicinium and Proxinium, are locally-administered TPTs. In the third quarter of 2015, we commenced a Phase 3 clinical trial for our lead product candidate, Vicinium, for the treatment of high-grade non-muscle invasive bladder cancer, or NMIBC, in the United States and Canada. We intend to seek input by the end of the first quarter of 2016 and begin enrollment in a Phase 3 clinical trial of Proxinium for the treatment of late-stage squamous cell carcinoma of the head and neck, or SCCHN, in the United States. Similar to existing antibody-drug conjugates, or ADCs, our TPTs are comprised of a targeting moiety that specifically binds to cancer cells and delivers a cytotoxic payload. We have designed our TPTs to overcome the fundamental efficacy and safety challenges inherent in existing ADCs.

Employees: 26
Founded: 2013
Contact Information
Address 147 Hamelin Street, Winnipeg, MB R3T 3Z1, Canada
Phone Number 204-478-1023
Web Address
View Prospectus: Viventia Bio
Financial Information
Market Cap
Revenues $0.0 mil (last 12 months)
Net Income $-8.9 mil (last 12 months)
IPO Profile
Symbol VITA
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $86.3 mil
Manager / Joint Managers Leerink Partners/ Cowen and Company/ Guggenheim Securities
CO-Managers -
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change